论文部分内容阅读
目的:探讨雌激素受体(ER)、孕激素受体(PR)在子宫内膜良恶性组织中的表达及其临床意义。方法:采用LSAB法对33例子宫内膜癌、39例子宫内膜单纯型增生、31例子宫内膜非典型增生及31例正常子宫内膜标本进行ER、PR的检测。结果:ER、PR在子宫内膜单纯型增生(46.15%、66.67%)、非典型增生(48.38%、64.52%)及子宫内膜癌(60.61%、60.61%)中的阳性表达率明显高于正常子宫内膜(19.35%、25.82%),P<0.05。且ER、PR阳性表达强度在单纯型增生、非典型增生、子宫内膜癌与正常内膜之间差异有统计学意义(P<0.05)。ER阳性表达率在子宫内膜癌组织分化之间的差异有统计学意义(P<0.05)。但ER、PR阳性表达率在其年龄、临床分期及绝经情况方面的差异均无统计学意义。结论:子宫内膜癌发生发展中可出现ER、PR异常表达,为临床内分泌治疗提供理论依据。
Objective: To investigate the expression of estrogen receptor (ER) and progesterone receptor (PR) in benign and malignant endometrium and its clinical significance. Methods: ER, PR were detected by LSAB in 33 cases of endometrial carcinoma, 39 cases of endometrial hyperplasia, 31 cases of endometrial dysplasia and 31 cases of normal endometrium. Results: The positive rates of ER and PR in endometrial hyperplasia (46.15%, 66.67%), atypical hyperplasia (48.38%, 64.52%) and endometrial carcinoma (60.61%, 60.61%) were significantly higher than Normal endometrium (19.35%, 25.82%), P <0.05. The positive expression intensity of ER and PR in simple hyperplasia, atypical hyperplasia, endometrial carcinoma and normal endometrium was significantly different (P <0.05). The difference of ER positive expression rate between endometrial carcinoma tissues was statistically significant (P <0.05). However, the positive rates of ER and PR were not significantly different in their age, clinical stage and menopausal status. Conclusion: The abnormal expression of ER and PR may occur during the development of endometrial carcinoma, providing a theoretical basis for clinical endocrine therapy.